Veracyte announces data for prostate genomic classifier

By staff writers

September 22, 2022 -- Veracyte said on Thursday that data published in the Journal of the National Cancer Institute (JNCI) demonstrated that its Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.

p>The data came from Veracyte's prospective, multisite VANDAAM Phase 2 clinical study, which enrolled men with low- or intermediate-risk prostate cancer as defined by the National Comprehensive Cancer Network (NCCN) into a cohort of 226 men (113 African American and 113 non-African American), the company said. Investigators used Veracyte's Decipher Prostate Genomic Classifier to perform genomic analyses and generate risk scores.

A higher proportion of African American men with low- or immediate-risk prostate cancer had higher Decipher risk scores. Additionally, younger African American men had higher Decipher scores, whereas older non-African American men had higher risk of metastasis scores.

"This study demonstrates that prostate cancer risk classification using clinical factors alone may be suboptimal and may underestimate African American men's risk of harboring aggressive disease," Elai Davicioni, medical director of urology at Veracyte, said in a statement.

The data suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes, Veracyte said.

Allelica launches polygenic risk score analysis as LDT
Allelica on Wednesday announced the launch of an ancestry-specific polygenic risk score (PRS) analysis as a laboratory-developed test (LDT) for coronary...
Veracyte announces data at ESMO 2022 for prostate genomic classifier
Veracyte on Sunday announced new data confirming that its Decipher Prostate Genomic Classifier can identify men with advanced prostate cancer who are...
Veracyte touts results of Percepta genomic sequencing study
Veracyte has released data from a study that used the company's Percepta genomic sequencing classifier, which the company reported can deliver curative...
Veracyte to highlight Decipher clinical data at ASCO
Veracyte plans to highlight results at the virtual American Society of Clinical Oncology (ASCO) from two studies that show its Decipher prostate genomic...

Copyright © 2022

Last Updated mp 9/22/2022 12:36:46 PM